SIRL-1, Human, mAb 1A5
The monoclonal antibody 1A5 recognizes human Signal inhibitory Receptor on Leucocytes-1 (SIRL-1). In order to prevent host tissue damage immune activation has to be tighly regulated. Neutrophils and other myeloid cells have a pivotal role in controlling infection. They form the primary response at site of infection as they regulate replication of pathogens by phagocytosis, secretion of antimicrobial peptides and proinflammatory cytokines to activate the immune system. Without regulation these mediators can cause tissue damage or worse. To balance the immune response immune cells can express inhibitory receptors.
The family of immune inhibitory receptors is still expending. The relatively new receptor SIRL-1 is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-bearing membrane protein expressed on human phagocytes. SIRL-1 contains two ITIMs in the intracellular tail, which are crucial for function. SIRL-1 can recruit the SH2-domain containing tyrosine phosphatases, SHP-1 and SHP-2, which may mediate the inhibitory effect. ITIM-bearing receptors inhibit signals relayed by immunoreceptor tyrosine-based activating motifs (ITAMs). ITAMs are the principal mediators of signal transduction for various receptors, including FcRs and C-type lectins.
The ligation of SIRL-1 dampens Fc receptor induced ROS production in phagocytes, thereby impairing the microbicidal activity of neutrophils without affecting phagocytosis. Infectious stimuli cause rapid downregulation of SIRL-1 expression. This allows microbial killing and clearance of pathogens.
Neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). Using anti SIRL-1 antibodies both spontaneous anti-neutrophil antibody induced NET formation is suppressed. This suggests a regulatory role for SIRL-1 in NET formation and a therapeutic target for regulation of SLE.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA